Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Low dose haptenized tumor cell and tumor cell extract immunotherapy

a tumor cell and immunotherapy technology, applied in the field of low dose haptenized tumor cells and tumor cell extract immunotherapy, can solve the problems of not reaching 100%, not being established that these haptens will be effective in humans, etc., and achieve the effect of more effective treatment regimens

Inactive Publication Date: 2005-10-20
BERD DAVID
View PDF14 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0018] Thus, one object of the invention is to provide more effective treatment regimens in the field of cancer vaccines by priming the immune system with a haptenized or non-haptenized tumor cell preparation.

Problems solved by technology

However, it has not been established that these haptens will be effective in humans; on the contrary, Nahas and Leskowitz, supra, suggest otherwise.
Nevertheless, there remains a need in the art for even more effective therapies, since the response rates achieved with the haptenized tumor cell vaccine technologies mentioned above, while impressive, have not reached 100%.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Low dose haptenized tumor cell and tumor cell extract immunotherapy
  • Low dose haptenized tumor cell and tumor cell extract immunotherapy

Examples

Experimental program
Comparison scheme
Effect test

example 1

Treatment Protocol for Melanoma Patients

[0095] Patient group. The treatment efficacy of DNP-modified autologous melanoma cells (vaccine) is studied in post-surgical stage III melanoma patients having metastatic lymph node involvement, or stage IV melanoma patients with lung metastases. Prior to the initiation of the vaccine treatment, preferably within two months from the starting point, one or more tumor masses are surgically resected from each patient. For axillary nodes, a formal axillary node dissection is performed. For inguinal nodes, a superficial inguinal dissection is performed, with a deep dissection at the discretion of the surgeon. For other lymph node-bearing areas, an appropriate node dissection is performed. An adequate tumor sample, approximately 2 cm or 5 g, yielding at least about 50×106 cells, is kept under sterile conditions to be used for vaccine preparation. Patients are preferably confirmed melanoma-free by computed tomography (CT) or magnetic resonance imagi...

example 2

Pretreatment with BCG-free Haptenized Tumor Cells Improves Therapeutic Outcome

[0101] Anti-metastatic effects are induced by DNP-modified, irradiated, autologous tumor cell vaccine (preceded by low-dose cyclophosphamide) in a newly developed animal model, (described in co-pending application Ser. No. 60 / 180,257, attorney docket No. 1225 / 0G680, filed on Feb. 4, 2000). This animal model, particularily useful for providing information on the effectiveness of postsurgical immunotherapies for recurrence of metastatic disease, was used to evaluate whether a modified protocol could offer even greater therapeutic benefits. Specifically, treatment regimen (A), consisting of low-dose cyclophosphamide followed by unmodified or DNP-modified autologous (syngeneic) tumor cell vaccine, was compared to a new pretreatment regimen (B), in which a single dose of autologous DNP-modified tumor cells (free of BCG) was administered prior to initiation of the low-dose cyclophosphamide treatment, followed b...

example 3

The Timing of an Haptenized or Non-Haptenized, Irradiated, Autologous, Melanoma, Tumor Cell Treatment Prior to Administration of an Immunomodulator and an Haptenized Vaccine Improves Therapeutic Outcome

[0111] The anti-metastatic effects of hapten-modified vaccines are increased by the administration of a “priming” induction dose administered several days before administration of a low dose of the immunomodulator cyclophosphamide (CY) and DNP vaccine mixed with BCG. The induction (or “priming”) dose comprised of one of the three following compositions: (1) 106 irradiated, autologous, tumor cells (AU TC); (2) a mixture of irradiated, autologous, tumor cells and irradiated, autologous, DNP-modified tumor cells 106 of each; or (3) 106 irradiated, autologous, DNP-modified tumor cells.

Material and Methods

[0112] Patient group. The treatment efficacy of administering a “priming” induction dose of haptenized or non-haptenized or a mixture of haptenized and non-haptenized, irradiated, auto...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Timeaaaaaaaaaa
Timeaaaaaaaaaa
Login to View More

Abstract

This invention relates to compositions comprising haptenized tumor cells and extracts thereof, methods for preparing the compositions, vaccines comprising such haptenized tumor cells, and methods for treating cancer with such vaccines. In a specific embodiment, melanoma cells are haptenized with a dinitrophenyl group, and used for treatment of melanoma patients having metastatic disease. Preferably, patients are given a first vaccine dose containing haptenized cells to “prime” the immune system. Subsequently, patients are injected with an immunomodulatory compound such as cyclophosphamide. In a preferred embodiment, an appropriate time period after the “priming” vaccine dose, additional vaccine doses containing a mixture of haptenized cells and an adjuvant are administered. The described treatment plan is more effective for eliciting favorable anti-tumor immune responses.

Description

FIELD OF THE INVENTION [0001] The invention relates to compositions comprising haptenized tumor cells and extracts thereof. The invention also relates to methods for treating cancer in which a priming dose of a hapten-modified tumor cell preparation is administered prior to any immunomodulatory agent that potentiates protective anti-tumor immunity or inhibits immune suppression, or both, such as, e.g., cyclophosphamide, and prior to compositions comprising a mixture between an immunological adjuvant and haptenized tumor cells or tumor cell extracts. BACKGROUND OF THE INVENTION Haptenized Tumor Cell Vaccines [0002] An autologous whole-cell vaccine modified with the hapten dinitrophenyl (DNP) has been shown to produce inflammatory responses in metastatic sites of melanoma patients. The survival rates of patients receiving post-surgical adjuvant therapy with DNP-modified vaccine are markedly higher than those reported for patients treated with surgery alone. Intact cells are preferred ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/00A61P35/00A61P37/04
CPCA61K39/0011A61K2039/6012A61K2039/55594A61K2039/5152A61P35/00A61P37/04
Inventor BERD, DAVID
Owner BERD DAVID
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com